Multimodality imaging evaluation of Chagas disease:an expert consensus of Brazilian Cardiovascular Imaging Department (DIC) and the European Association of Cardiovascular Imaging (EACVI) by Nunes, Maria Carmo P et al.
                          Nunes, M. C. P., Badano, L. P., Marin-Neto, J. A., Edvardsen, T., Fernández-
Golfín, C., Bucciarelli-Ducci, C., ... Lancellotti, P. (2018). Multimodality
imaging evaluation of Chagas disease: an expert consensus of Brazilian
Cardiovascular Imaging Department (DIC) and the European Association of
Cardiovascular Imaging (EACVI). European Heart Journal - Cardiovascular
Imaging, 19(4), 259-460n. https://doi.org/10.1093/ehjci/jex154
Peer reviewed version
License (if available):
Other
Link to published version (if available):
10.1093/ehjci/jex154
Link to publication record in Explore Bristol Research
PDF-document
This is the accepted author manuscript (AAM). The final published version (version of record) is available online
via Oxford University Press at https://doi.org/10.1093/ehjci/jex154 . Please refer to any applicable terms of use
of the publisher.
University of Bristol - Explore Bristol Research
General rights
This document is made available in accordance with publisher policies. Please cite only the published
version using the reference above. Full terms of use are available:
http://www.bristol.ac.uk/pure/about/ebr-terms
1 
 
Multimodality Imaging Evaluation of Chagas disease – an Expert 
Consensus of Brazilian Cardiovascular Imaging Department (DIC) 
and the European Association of Cardiovascular Imaging (EACVI) 
 
Maria Carmo P Nunes, MD, PhD1; Luigi Paolo Badano, MD, PhD, FESC, FACC2, J. 
Antonio Marin-Neto, MD, PhD3; Thor Edvardsen, MD, PhD4; Covadonga Fernández-
Golfín,MD5; Chiara Bucciarelli-Ducci, MD, PhD6; Bogdan A. Popescu MD, PhD7; 
Richard Underwood,MD8; Gilbert Habib, MD, PhD9; Jose Luis Zamorano, MD, PhD10; 
Roberto Magalhães Saraiva, MD, PhD11; Ester Cerdeira Sabino, MD; PhD12; Fernando 
A Botoni, MD,PhD1; Márcia Melo Barbosa, MD; PhD1; Marcio Vinicius L Barros, MD, 
PhD1; Eduardo Falqueto, MD13; Marcus Vinicius Simões; MD, PhD,3 André Schmidt, 
MD, PhD3; Carlos Eduardo Rochitte, MD, PhD14; Manoel Otávio Costa Rocha, MD, 
PhD1, and Antonio Luiz Pinho Ribeiro, MD, PhD1; Patrizo Lancellotti, MD; PhD15. 
 Institutions  
1: School of Medicine and Hospital das Clínicas of the Federal University of Minas 
Gerais, Belo Horizonte, MG, Brazil   
2: Department of Cardiac, Thoracic and Vascular Sciences, University of Padova, 
Padova, Italy  
3: School of Medicine of Ribeirão Preto of the University de Sao Paulo (USP), Brazil    
4: Department of Cardiology, Oslo University Hospital and University of Oslo, Oslo, 
Norway 
5: Hospital Universitario Ramón y Cajal, Madrid, Spain 
6: Bristol Heart Institute, Bristol NIHR Biomedical Research Unit, University of 
Bristol, Bristol, UK 
7: University of Medicine and Pharmacy ‘Carol Davila’ - Euroecolab, Institute of 
Cardiovascular Diseases ‘Prof. Dr. C. C. Iliescu’, Bucharest, Romania  
8: Royal Brompton Hospital and Harefield Hospital, London, United Kingdom 
9: La Timone Hospital, Marseille, France 
10: University Alcala Hospital Ramon y Cajal, Madrid, Spain 
11: Evandro Chagas National Institute of Infectious Diseases, Oswaldo Cruz 
Foundation, Rio de Janeiro, Brazil 
12: School of Medicine of the University de Sao Paulo (USP), Sao Paulo, Brazil  
13: Hospital Felicio Rocho, Belo Horizonte, MG, Brasil   
14: Instituto do Coração (InCor), School of Medicine of USP & Hospital do Coração, 
HCor, Heart Hospital, Associação do Sanatório Sírio, São Paulo, Brazil 
15: University of Liège Hospital, GIGA Cardiovascular Sciences, Departments of 
Cardiology, Heart Valve Clinic, CHU Sart Tilman, Liège, Belgium; and Gruppo Villa 
Maria Care and Research, Anthea Hospital, Bari, Italy 
 
Address for correspondence: Prof. Maria Carmo P Nunes - Department of Internal 
Medicine, School of Medicine of the Federal University of Minas Gerais. Av. Professor 
Alfredo Balena, 190, Santa Efigênia, 30130 100 – Belo Horizonte, MG, Brazil 
Phone: +55 31 34099746  Fax: +55 31 34099437 Email: mcarmo@waymail.com.br 
 
2 
 
DOCUMENT OUTLINE  
 
1. Introduction 
2. Natural history and clinical manifestations 
3. Left ventricular systolic function 
3.1 Echocardiography 
3.2 Cardiac magnetic resonance 
3.3 Nuclear cardiology 
4. Left ventricular diastolic function 
5. Right ventricular function 
5.1 Echocardiography 
5.2 Cardiac magnetic resonance 
5.3 Nuclear cardiology 
6. Coronary circulation  
6.1 Stress echo and coronary flow reserve 
6.2 Myocardial perfusion scintigraphy 
7. Myocardial sympathetic innervation  
8. Patient risk stratification 
9. Conclusion and future research 
 
3 
 
 
Abbreviations: 
 
123I-MIBG, iodine-123-metaiodobenzylguanidine  
CCM, Chagas cardiomyopathy 
CMR, cardiac magnetic resonance 
LA, left atrium/atrial 
LGE, late gadolinium enhancement 
LV, left ventricle/ventricular 
RNV, radionuclide ventriculography 
RV, right ventricle/ventricular 
DEFINITIONS: Two terms will be used throughout the paper: "Chagas disease" is a 
broad term to describe the disease in general, as caused by the infection with the T. 
cruzi, and "Chagas cardiomyopathy" refers to a form of presentation of Chagas disease, 
characterized by left ventricular enlargement with systolic function impairment, 
prominent disturbances of electric generation and conduction causing sudden death and 
multiple thromboembolic manifestations.
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1: Introduction  
Chagas disease, caused by the protozoan Trypanosoma cruzi (T. cruzi), remains one of 
the most prevalent infectious diseases in Latin America, and has become a health 
problem in non-endemic countries.1, 2 Although public health programs have 
significantly reduced the prevalence of Chagas disease in Latin America in recent 
decades, awareness of the number of infections in the United States and non-endemic 
countries in Europe continues to rise.3 
Dilated cardiomyopathy is the most severe manifestation of Chagas disease and is 
characterized by heart failure, ventricular aneurysms, conduction disturbances, 
ventricular arrhythmias, thromboembolism, and sudden death.4, 5 The early mortality 
and substantial disability caused by this disease, which often manifests in the socially 
most productive population (i.e. young adults) result in a significant economical burden. 
Chagas cardiomyopathy (CCM) usually requires long-term treatment, and can include 
specialized care, with pacemaker and cardioverter defibrillator implantation, and heart 
transplantation, with further increase of the costs related to the disease.6  
The pathogenesis of chronic CCM has not been completely elucidated. Most 
investigators believe that the main pathogenetic mechanisms of CCM are dependent on 
the parasite driven inflammatory reaction and the adverse host immune response.7 
Autoimmunity mechanisms, probably related to the parasite persistence, involving 
polyclonal activation, molecular self-mimicry by parasite antigens or cryptic epitopes 
may also be implicated in the development of CCM7. Two other mechanisms are 
thought to contribute to the pathogenesis of CCM: neurogenic disturbances and 
microvascular derangements. 7, 8  
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Prompt and correct diagnosis of Chagas disease requires specialized clinical expertise to 
recognize the unique features of this disease. The appropriate and efficient use of 
cardiac imaging is pivotal for diagnosing the cardiac involvement in Chagas disease, to 
stage the disease, assess patients’ prognosis and address management.  
Accordingly, Brazilian Cardiovascular Imaging Department (DIC) and the European 
Association of Cardiovascular Imaging (EACVI) developed this document to review 
and summarize the most recent evidences about the non-invasive assessment of patients 
with Chagas disease, with the intent to set up a framework for standardized and efficient 
use of cardiovascular imaging to assess cardiovascular morphologic and functional 
disturbances, as well as to guide the subsequent process of clinical decision-making.  9 
2: Natural history, diagnosis, clinical manifestations and prognosis 
Chagas disease is transmitted to humans by infected triatomine bugs, through blood 
transfusion, organ transplantation, congenital transmission, oral ingestion of 
contaminated materials, or accidental contamination during laboratory work. 10 The 
natural history of Chagas disease is characterized by two well-established phases 
(Figure 1). The acute phase, with high-grade parasitaemia and proliferation of 
amastigote forms in various organs, lasts from 4 to 8 weeks, is usually 
oligosymptomatic and is diagnosed in only 1 to 2% of the cases. The mortality rate is 
around 1% in the acute period, usually due to severe myocarditis or 
meningoencephalitis tissues.11, 12 Given the high rates of pericardial effusion, 
echocardiography is indicated in patients with acute T. cruzi infection, irrespective of 
symptoms. 
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The chronic phase is characterized by two distinct clinical forms. The indeterminate 
form, which is usually installed 4 to 10 weeks after infection, is defined by 
seropositivity, and lack of radiologic, electrocardiographic and clinical manifestations 
of cardiac and digestive disease. 13  However, cardiovascular abnormalities can be 
detected using specific non-invasive tests, such as echocardiogram,14, 15 cardiac 
magnetic resonance (CMR) and autonomic tests.16-18. Although most patients remain 
with the indeterminate form throughout life, others evolve to a determined form of the 
disease 10-30 years after the acute infection, affecting specific organs, such as the heart, 
esophagus and colon, which characterize distinct chronic cardiac, digestive or mixed 
forms.19 The progression from indeterminate to cardiac form ocurrs at an average rate of 
around 2% per year. 20, 21  
The cardiac form is usually initially defined by the presence of typical 
electrocardiographic abnormalities that encompass a wide spectrum of presentations, 
from minor electrocardiographic alterations with normal left ventricular (LV) systolic 
function, to various forms of arrhythmia, and to dilated cardiomyopathy with heart 
failure.13, 22, 23 The CCM, which constitutes the most serious complication of the 
disease, occurs in 20-40% of those individuals tested serologically positive .24 Up to 15–
20% of patients with indeterminate form develop digestive alterations in some endemic 
areas, but the prevalence seems to vary among countries possibly due to different 
inoculated strain.25  
The chronic cardiac form manifests itself by one of the three main syndromes, which 
can occur in association: heart failure, cardiac arrhythmias, and pulmonary or systemic 
thromboembolism. The initial manifestations of CCM are generally mild and most 
patients have asymptomatic ECG alterations, such as right bundle branch block and 
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bradycardia,26 and minor echocardiographic abnormalities, e.g. regional wall motion 
abnormalities.27 (Table 1). The greater the extent of the myocardial damage, 
particularly LV dilatation, the more frequent and complex are the ECG abnormalities, in 
particular more complex ventricular arrhythmias and atrial fibrillation.28  
Patients with more advanced disease frequently have heart failure, which is associated 
with an ominous prognosis and seems to be carrying higher mortality risk than ischemic 
or idiopathic dilated cardiomyopathies.29, 30  
Stroke is also a cause of death in association with advanced heart disease,31 but could 
also be the first sign of CCM in asymptomatic patients and those with mild LV systolic 
dysfunction.32 LV aneurysm, mural thrombus, and atrial fibrilation are risk factors for 
stroke related to CCM. 
CCM is a frequent cause of pacemaker implantation in patients living or coming from 
endemic countries, since advanced heart blocks and sinus sick syndrome are common 
manifestations of the disease.33 Ventricular arrhythmias are important manifestations of 
CCM and non-sustained ventricular tachycardia is an established marker of higher risk 
of death.34, 35 Patients with sustained ventricular tachycardia may require specific 
therapies, especially invasive procedures such as the implantation of cardioverter 
defibrillators and catheter or surgical ablation.36    
The etiologic diagnosis of chronic Chagas disease is based on serological assays 
because the direct detection of parasites is difficult due to very low levels or even 
absence of parasitaemia.37 There are several techniques used for detection of antibodies 
against the T. cruzi including indirect immunofluorescence, enzyme immunoassays 
(ELISAs), hemaglutination and rapid test provided by different manufacturers.38 Their 
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sensitivity may vary significantly and Chagas disease should be screened by 2 different  
parallel assays.39 However, as the ELISA tests were more broadly used in the blood 
bank setting, the sensitivity of the assays improved and the current predominant 
consensus is that a single highly sensitive assay can be used for the initial T. cruzi 
screening, so that, if negative, it would rule out this etiology.38  
Regarding the prognosis of the disease, Chagas disease is a powerful predictor  of 
death,40 even in the elderly.31 Several risk markers have been recognized, and a 
systematic review identified that impaired LV function, New York Heart Association 
class III/IV, cardiomegaly, and nonsustained ventricular tachycardia are the most 
important predictors of poor prognosis in patients with chronic Chagas cardiomyopathy. 
41 Using a validated prognostic scoring system, based on clinical, radiological, 
echocardiographic and Holter monitoring/stress testing, Chagas disease patients can be 
stratified into three risk groups: low, intermediate, and high.34 For those at low risk, 
90% will still be alive after ten years, in comparison with only 16% of those at high 
risk. Prognostic factors have been used to build a risk score for death that is helpful for 
clinical-decision making. 34 (Table 2).  
Key Points: 
- 20-40% of patients with Chagas disease will evolve to chronic Chagas 
cardiomyopathy, which can be asymptomatic or manifest by heart failure, 
cardiac arrhythmias, and/or thromboembolism 
- Brady or tachy-arrhythmias or stroke may be the first manifestation of Chagas 
cardiomyopathy 
- Chronic form of Chagas cardiomyopathy evolving to heart failure carries higher 
mortality compared to other etiologies of heart failure.  
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- The etiologic diagnosis of chronic Chagas disease is based on serological assays 
- Impaired LV systolic function, New York Heart Association class III/IV, 
cardiomegaly, and nonsustained ventricular tachycardia are important predictors 
of poor prognosis in patients with chronic Chagas disease 
3. Left ventricular systolic function 
3.1 Echocardiography  
Echocardiography is the most commonly used imaging modality for assessment and 
follow-up of patients with Chagas disease. 42 The presence of echocardiographic 
abnormalities is of utmost importance, since it allows to stage patients (A, B, C and D) 
according to international recommendations adapted to the Chagas disease (Table 1). 13, 
42 In early stages of cardiac involvement, echocardiography may demonstrate segmental 
LV wall motion abnormalities and diastolic dysfunction.4, 43, 44 The most commonly 
involved LV regions are the basal inferior and inferolateral walls (Figure 2), and the 
apex, which cannot be attributed to obstructive coronary artery. 45 Wall motion 
abnormalities can be detected in more than one wall in the same patient. The extent of 
regional wall motion abnormality varies from hypokinesis to akinesis and aneurysm. 
The presence of segmental abnormalities identifies individuals at risk of further LV 
function global deterioration.46   
The prevalence of segmental wall motion abnormalities varies according to the stage of 
the disease. Wall motion abnormalities can be found in around 10% of patients in the 
early stages of cardiac involvement and they can be associated with ventricular 
arrhythmias.47 As the disease progresses to LV dilatation and dysfunction, the 
prevalence of segmental wall motion abnormalities increases to about 50% of patients. 
48, 49  
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Detection of regional wall motion abnormalities by visual assessment is subjective and 
highly dependent on the skills of the interpreter. Moreover, subtle changes in segmental 
contractility may be missed by visual assessment. Strain measurement using speckle 
tracking echocardiography is a new method that allows a more precise and quantitative 
measurement of the regional myocardial function, overcoming the subjective evaluation 
by conventional echocardiography (Figures 3 and 4).50, 51 Since segmental wall motion 
abnormalities are frequent in Chagas disease, speckle tracking echocardiography may 
have an important clinical application in these patients, particularly in the indeterminate 
forms when abnormalities are more subtle. A study including 125 patients with Chagas 
disease found that global longitudinal, circumferential, and radial LV strain were 
reduced in the patients who had cardiac fibrosis on CMR despite normal global and 
segmental LV systolic function by echocardiography.52 Specifically the patients with 
fibrosis had lower radial LV strain   in the basal inferoseptal wall than patients without 
cardiac fibrosis (27 ± 17% vs 60 ± 15%).  
Speckle tracking echocardiography can also quantify the heterogeneity of systolic 
contraction, which is associated with the risk of arrhythmic events. A recent study 
showed that mechanical dispersion was associated with malignant ventricular 
arrhythmias in patients with CCM independent of LV ejection fraction (Figure 5). 53  
LV apical aneurysms are a typical finding in patients with CCM and can be helpful in 
making the etiologic diagnosis in dilated cardiomyopathy (Figure 6).4, 45, 48 This 
abnormality may be missed if only conventional apical views are acquired. In order to 
identify aneurysms, a careful examination requires not only standard views but also 
angulated apical views. Frequently, a modified 4 and 2-chambers views aiming 
posteriorly may be necessary to detect apical aneurysms and thrombus. The size of the 
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aneurysm may range from small (like a ‘hollow punch’) to large with extensive wall 
thinning, similar to ischemic aneurysms. 45, 48 Aneurysms are not limited to the apex or 
to the inferolateral wall 45, they can also be found in interventricular septum and 
anterolateral walls, being more prevalent in patients with global LV systolic 
dysfunction.45, 48 Previous studies using 2D echocardiography reported that the LV 
aneurysm prevalence was 8.5% (ranging from 1.6% to 8.6%) in asymptomatic patients 
but increased to 55% (ranging from 47% to 64%) in patients with moderate or severe 
LV global systolic dysfunction.45, 48, 49 Right ventricular (RV) aneurysms are 
uncommon, but some patients have apical aneurysms affecting both ventricles (Figure 
7). Intraventricular mural thrombi can be associated with aneurysms and are important 
risk factors for the occurrence of systemic embolisms including stroke 54-57(Figures 8 
and 9).  
Contrast echocardiography has the advantage to enhancement of LV endocardial border, 
allowing for more accurate detection of ventricular aneurysms and thrombus in Chagas 
disease.45 With the apical 4-chamber view, using contrast echo, it should be usually 
possible to clearly  
visualize the RV and LV cavities.   
In Chagas disease, three-dimensional echocardiography is superior to 2D echo for 
assessing more accurately the LV apex and thus to detect apical aneurysms/thrombus in 
patients in whom LV foreshortening is suspected by 2D echo. (Figure 10)  In addition, 
3D echo is more accurate than 2D Simpson’s biplane rule for assessing LV volumes and 
EF in patients with significant wall motion abnormalities, including aneurysms with 
distorted LV geometry.  
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Although segmental wall motion abnormalities are among the most characteristic 
findings of cardiac involvement in Chagas disease, their pathogenesis has not been 
defined. Since the epicardial coronary arteries are angiographycally normal it has been 
hypothesized that microvascular involvement leads to ischemia and necrosis in distal 
watershed areas of the coronary territories (Figure 11). 58, 59 This could explain the 
prevalence of fibrotic lesions 58 and perfusion defects in inferior, inferolateral and apical 
segments.59 Accordingly, the regions of late gadolinium enhancement (LGE) (signifying 
myocardial fibrosis/scarring) in the post-contrast cardiac magnetic resonance (CMR) 
images are predominantly localized in the apex, inferior and inferolateral walls. 60 
More advanced disease is characterized by global LV dilatation and diffuse 
hypokinesia. LV systolic dysfunction is the strongest predictor of death in CCM. 61, 62 
Key points: 
- Echocardiography is the most common imaging modality used to assess, stage, 
and follow-up of patients with Chagas disease 
- In early stages of cardiac involvement, echocardiography may demonstrate 
segmental LV wall motion abnormalities 
- Segmental wall motion abnormalities are more frequent in inferior and inferior-
lateral walls and at the apex and may range from hypokinesis to aneurysms 
- Apical aneurysms are the landmark lesions in Chagas disease, but they can be 
missed in conventional 2D apical views due to apical foreshortening, dropout or 
near-field artifacts 
- The use of contrast is highly recommmended whenever the image quality is 
suboptimal (> 2 LV segments not visible, as recommended by guidelines) and 
when apical involvement is either suspected or unclear 
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- Speckle tracking longitudinal strain and 3D echocardiography appear to be 
accurate and reproducible methods to assess LV systolic function in Chagas 
disease and should be used when available and feasible 
- More advanced stages of Chagas disease are characterized by global left 
ventricular remodeling and dysfunction 
 
- 3.2 Cardiac magnetic resonance  
Due to its unique ability to differentiate tissue characteristics, CMR allows non-
invasive tissue characterization in CCM. CMR can demonstrate all the typical 
features of the cardiac involvement in Chagas disease such as the presence of 
myocardial edema, and altered myocardial perfusion in the early stages, as well as 
global and segmental wall motion abnormalities, aneurysm formation, intracardiac 
thrombi and myocardial fibrosis areas detected by the late gadolinium enhancement 
(LGE) sequence in the most advanced stages (Figures 12). 
A study 63 showed that 20% of patients in the indeterminate form of Chagas disease 
have evidence of myocardial fibrosis, without any associated wall motion 
abnormality. In CCM, CMR highlights the structural derangement associated with 
intense collagen formation. Moreover, the apical aneurysms can be easily 
demonstrated by CMR (Figure 13). In advanced stages, the cine sequences show 
decreased global contractility and ejection fraction with diffuse parietal thinning.63  
Regions of LGE with a heterogeneous pattern at delayed enhancement CMR images 
have been reported in 68.6% of patients at different stages of Chagas disease.60 The 
extension of myocardial fibrosis correlated with the severity of the LV systolic 
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dysfunction, which was also present in all patients with previously documented 
episodes of ventricular tachycardia.60  
Another study 64 reported that, in patients with Chagas disease the prevalence of 
LGE  was 24% in the overall study population. Particularly, in patients with only 
electrocardiographic abnormalities, LGE was found in 16% of patients and 3% had 
segmental dyskinesia (aneurysm) not detected with echocardiography. Conversely 
52% of the patients with CCM had LGE indicating myocardial fibrosis and/or 
necrosis. The LGE appearance was heterogeneous: subendocardial in 26.8%, 
midwall in 14.0%, subepicardial in 22.6%, and transmural in 36.0% of the patients. 
The presence of LGE was significantly associated with lower LV ejection fraction 
and was more commonly located at the apex and inferolateral walls. In this study, a 
correlation between LGE and arrhythmic events was identified. Thus, early 
detection of edema and/or myocardial fibrosis by CMR may potentially identify 
patients at risk of disease progression60.   
In 41 patients with Chagas disease and cardiac involvement, myocardial fibrosis 
was detected in all the 26 patients (63%) who had ventricular tachycardia65. The 
presence of two or more LV segments containing transmural LGE constituted a 
predictor of the occurrence of arrhythmia after adjustment for LV ejection fraction, 
age, gender and the area of LGE. Patients without previous ventricular tachycardia, 
or transmural LGE, and those with less than 6% of fibrosis in the myocardium 
showed no new arrhythmic events. Furthermore, three patients died of sudden death, 
and all of them had at least one segment with transmural LGE at CMR and no 
previous history of ventricular tachycardia 65.  
Key points 
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- Cardiac magnetic resonance should be indicated  in selected patients with 
severe ventricular arrhythmias to quantify the extension of myocardial 
fibrosis and risk of sudden death with potential impact on indicaton of  
implantable cardioverter-defibrillator.  
- Cardiac magnetic resonance should be indicated for LV ejection fraction  
evaluation when contrast echocardiography/3D echo is not available or 
unsatisfactory  
- It remains to be clarified whether in the patients with the indeterminate form 
of the disease, evidence of edema or fibrosis at CMR can predict future 
progression to the cardiomyopathy 
 
3.3 Radionuclide ventriculography 
Planar ECG-gated radionuclide ventriculography (RNV) is an alternative method for 
biventricular function assessment in patients with suspected or definite cardiac 
involvement in Chagas disease with suboptimal acoustic window and contraindication 
to CMR.66  RNV was used initially to assess global LV function, and also allows the 
adequate evaluation of regional ventricular wall motion, particularly the characterization 
of the apical aneurysm, the most typical wall motion abnormality in Chagas heart 
disease.66 
Key points 
- Radionuclide ventriculography is used for biventricular function assessment in 
those patients in whom echocardiography presents limitation for adequate 
quantitative evaluation   
- Radionuclide ventriculography should be indicated for LV ejection fraction  
measurement and regional wall motion evaluation when contrast 
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echocardiography/3D echo is not available or unsatisfactory 
 
4. Left ventricular diastolic function  
Chagas disease may also lead to impairment of diastolic function, which can occur early 
in the disease.14, 44, 67  Usually, the first abnormality is impaired LV relaxation with 
prolonged E-wave deceleration time. Further progression of the disease leads to 
decreased LV compliance and results in increased filling pressures.4, 24, 52, 67  
LV diastolic dysfunction has been reported in all forms of chronic Chagas disease, 
including those without LV systolic dysfunction, but its prevalence and severity 
gradually increases from the indeterminate form to the more advanced stages of the 
cardiac form. In some studies prevalence of diastolic abnormality ranges from 10% of 
patients with indeterminate form to almost 100% in patients with CCM and heart 
failure. 44, 49, 67. Other studies enrolling patients with the indeterminate form did not 
show any impairment of diastolic function.68, 69  Differences regarding patient 
population sampling, controls selection and echocardiographic diastolic parameters used 
to define diastolic dysfunction, may explain discrepant results.  
More recently, key variables to assess LV diastolic function including tissue Doppler 
imaging have been used, which allows comparison among the studies. In particular, e’ 
velocity at tissue Doppler echocardiography appeared to be the best parameter to 
identify the progressive worsening of the LV diastolic dysfunction.44, 67   
Echocardiographic parameters of diastolic function in CCM are also correlated with 
brain natriuretic peptide levels. 70-72 A previous study including 59 patients with dilated 
CCM showed a strong correlation between LA volume and BNP levels. 70 In another 
study BNP levels correlated with diastolic function patterns regardless of systolic 
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function. The E/e’ ratio was the only parameter of diastolic function that was 
independently associated with BNP levels. 71 
 
Key points: 
- Isolated left ventricular diastolic dysfunction is uncommon but may appear 
early in the natural history of chronic Chagas cardiomyopathy, and has been 
described in patients with the indeterminate form of the disease  
- Diastolic and systolic dysfunction coexist in most patients with more 
advanced stages of the disease 
- Left atrial volume and E/e’ ratio correlate with brain natriuretic peptide 
levels in Chagas cardiomyopathy 
5. Right ventricular function 
RV systolic dysfunction may be an early finding in the natural history of Chagas disease 
and has been detected in patients with the indeterminate and digestive forms .15, 73, 74 
Several indexes and methods have been used to describe RV dysfunction in patients 
with Chagas disease showing somewhat discrepant results. These mixed data may be 
attributed to the different methods used to assess RV function as well as to the 
composition of the various groups of patients included in each study. 
 
Isolated right-sided heart failure is not frequent and usually RV dysfunction is 
associated with LV dysfunction at advanced stages of Chagas cardiomyopathy.4, 24, 75 
However, direct damage to the RV myocardium due to Chagas disease itself can also 
contribute to RV dysfunction.76-78. It is important to emphasize that RV dysfunction 
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may occur without symptoms or signs of heart failure, but may be aggravated by the 
burden generated by chronic pulmonary hypertension secondary to LV systolic 
dysfunction. In such circumstances RV dysfunction carries an adverse prognostic 
meaning.(74) Also, the concomitance of RV dysfunction explains why systemic 
congestion can predominate over pulmonary congestion in some patients with heart 
failure due to CCM.(75). 
 
5.1 Echocardiography for RV function assessment      
A study assessing RV function in Chagas disease showed prolongation of RV free wall 
isovolumic contraction time in patients in the indeterminate form of Chagas disease 
compared to controls.15 RV free wall isovolumic contraction time was obtained by 
measuring the interval between the Q wave of the ECG and the beginning of the systolic 
wave at the tricuspid annulus using tissue Doppler imaging.  
In contrast, in a study assessing RV function by longitudinal speckle tracking strain in 
78 asymptomatic Chagas disease patients with normal LV function, showed no 
difference of strain values in patients compared to controls.68  
Another study in patients with CCM, 76 evaluating qualitatively RV morphology and 
function by 2D echocardiography found that RV dysfunction was associated with 
impairment of the LV function. Similarly, a further study reported that RV systolic 
dysfunction  was present only in CCM patients with left-sided HF, as assessed by RV 
tissue Doppler imaging, longitudinal speckle tracking strain, and tricuspid annular plane 
systolic excursion. 67  
RV systolic involvement is a marker of Chagas disease severity and represents a strong 
predictor of mortality. A study in 158 patients with dilated CCM found that RV 
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function, assessed by RV myocardial performance index was a predictor of death, 
independent of functional class and LV ejection fraction.77 Other subsequent studies 
assessing risk stratification in Chagas disease have confirmed the fundamental role of 
RV function in predicting prognosis.62, 75, 79  RV function has also been reported to be an 
important determinant of exercise capacity in CCM.80 In a study including 65 patients 
with Chagas heart disease, RV systolic annular velocity by tissue Doppler imaging was 
associated with peak VO2, regardless of the influence of age, gender, and LV systolic 
function80.  
The analysis of RV function by echocardiographic methods has several limitations.  
Novel echocardiographic techniques, including three-dimensional and 2D speckle-
tracking echocardiography seem promising.  However, the clinical values of these 
parameters need to be better established in patients with Chagas disease. 
  
5.2 Cardiac magnetic resonance 
Cardiac magnetic resonance (CMR) is considered a “gold standard” for RV 
morphological and functional assessment, especially to calculate RV volumes and 
ejection fraction. However, previous studies in Chagas disease using CMR have focused 
on the LV and there are limited data on RV function. In CCM patients with heart 
failure, CMR showed lower RV ejection fraction with higher end-systolic and end-
diastolic volumes in those patients with LV dysfunction compared to those with 
preserved LV systolic function.81    
 
5.3 Radionuclide ventriculography 
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Previous studies using RNV to assess quantitatively RV function have documented 
early and predominant RV dysfunction in patients with the indeterminate and 
gastrointestinal forms of Chagas disease.73, 74 This particular feature explains why heart 
failure syndrome in some CCM patients may present more prominent systemic than 
pulmonary congestion.78  (Figure 14) 
Key points 
- Early and predominant right ventricular dysfunction may be present in some 
patients with Chagas disease, and in some those with the isolated 
gastrointestinal or the indeterminate forms of Chagas disease 
- It remains to be clarified whether RV dysfunction is predominantly 
secondary to chronic pulmonary hypertension induced by LV systolic 
dysfunction or reflects primarily a direct myocardial damage  
- Limited data are available regarding RV function assessed by CMR in 
Chagas disease 
 
6. Disturbances of the coronary circulation  
Although the epicardial coronary arteries are angiographically normal in the vast 
majority of patients with Chagas disease studied because of atypical angina, there is 
limited evidence of abnormal regulation at the macrovascular level. 7 Moreover, much 
more evidence has been gatthered from several studies pointing to functional and 
structural microvascular derangements likely to contribute to ventricular dysfunction in 
Chagas disease. 59     
On the basis of sporadic cases of myocardial infarction occurring in Chagas patients 
with non-obstructed epicedial coronary arteries, coronary vasospasm has been 
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postulated to cause such events 82. However, controlled studies aiming at detection of 
abnormal macrovascular coronary regulation in Chagas patients produced mixed results, 
using various endothelium dependent and endothelium independent stimuli such as 
hyperventilation, nitrates, acetylcholine and adenosine 59, 83, 84.  
6.1 Stress echocardiography and coronary flow reserve 
A study with dipyridamole stress echocardiography showed that coronary flow reserve 
(CFR) was impaired in Chagas disease patients in indeterminate form compared to 
controls. 85 (Figure 15) The impaired CFR in Chagas disease patients supports the 
concept that perfusion abnormalities caused by disturbances of coronary blood flow 
regulation at the microvascular levels may play a role in Chagas disease progression. 
Wall motion abnormalities have been detected in the posteroinferior wall segments 
during standard dobutamine stress echocardiography in patients with Chagas disease 86, 
a finding that supports that myocardial damage in Chagas heart disease may be related 
to microvascular disturbances. In fact, segmental LV wall motion abnormalities are 
commonly detected at rest in Chagas heart disease, despite absence of hemodynamically 
significant obstructions of epicardial coronary arteries.  
Key points 
- most patients have angiographycally normal coronary arteries but it is 
uncertain if coronary regulation at the macrovascular level is impaired 
- coronary flow reserve may be impaired in the early stages of cardiac 
involvement 
- wall motion abnormalities may be induced during stress in Chagas disease 
patients despite angiographically normal coronary arteries 
- functional and structural abnormalities of coronary microcirculation may 
contribute to development and progression of ventricular dysfunction in 
Chagas disease 
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6.2 Myocardial Perfusion Scintigraphy 
In patients with CCM, reduced myocardial perfusion, both at rest and during exercise, 
was first reported by measuring global myocardial flow with the old 86Rubidium 
method 87, 88. Regional myocardial perfusion abnormalities in Chagas disease patients 
with normal coronary arteries have subsequently been confirmed by other independent 
investigators 89, 90. These findings were consistent with abnormal flow regulation at the 
microvascular level (Figure 16). Myocardial perfusion defects occur at early stages of 
Chagas disease at a microvascular level and precede the appearance of regional systolic 
wall motion abnormalities. 59, 90-93 These data further support the hypothesis that 
coronary microvascular disturbances may cause ischemic myocardial damage in CCM.  
Key points 
- Myocardial perfusion defects occur at early stages of cardiac involvement in 
Chagas disease, before the appearance of regional wall motion abnormalities 
- Perfusion defect locations are correlated with subsequent development of 
regional myocardial fibrosis  
- Detection of reversible ischemic defects predicts further deterioration of left 
ventricular systolic function 
 
7. Myocardial sympathetic innervation  
Necropsy studies documented severe cardiac autonomic denervation in CCM, more 
severe than in other cardiomyopathies 94, 95. Moreover, functional abnormalities of the 
reflex autonomic control of the heart rate have been demonstrated using several 
methods of investigation 7. More recently, studies using myocardial scintigraphy with 
iodine-123-metaiodobenzylguanidine (123I-MIBG) have shown that defects of 123I-
MIBG uptake can be documented in the majority (68%) of the patients with Chagas 
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disease. 59, 92, 96 Of note, 123I-MIBG defects were detected in 33% of the patients without 
any other evidence of cardiac involvement. Patients with more severe LV dysfunction 
presented a higher prevalence of 123I-MIBG defects (92%). The areas of myocardial 
sympathetic denervation were topographically correlated with the regions also 
exhibiting fixed and reversible myocardial perfusion defects and abnormal segmental 
LV wall motion. These areas were predominantly the inferior, postero-lateral and apical 
LV walls. (Figure 17) These findings suggested that myocardial sympathetic 
denervation is an early phenomenon in the pathophysiology of Chagas disease, 
preceding the development of regional LV wall motion abnormalities. This concept was 
corroborated by an independent study showing abnormal 123I-MIBG uptake even in 
patients with Chagas disease and no apparent cardiac involvement. 97 
One investigation in 26 patients with Chagas disease and normal or mildly reduced LV 
ejection fraction showed that patients with sustained ventricular tachycardia had higher 
123I-MIBG summed score and a higher number of mismatch defects (sympathetic 
denervation with preserved perfusion) per patient than patients with no arrhythmias.96 
Both groups had similar 99mTC-Sestamibi-SPECT summed score. The presence of ≥ 3 
mismatch defects was strongly associated with the occurrence of sustained ventricular 
tachycardia (93% sensitivity, 82% specificity). These findings suggest a possibly 
relevant role of myocardial sympathetic denervation as a triggering mechanism of 
malignant ventricular arrhythmias, and that 123I-MIBG imaging may be useful to stratify 
the risk of sudden cardiac death in Chagas disease.96  
Key points 
- Myocardial sympathetic denervation is an early occurrence in patients with 
Chagas disease and can be detected using myocardial scintigraphy with 
iodine-123-metaiodobenzylguanidine 
24 
 
- The extension of myocardial sympathetic denervation correlates with the 
severity of left ventricular dysfunction   
- Extent of cardiac sympathetic denervation  may be a marker of ventricular 
arrhythmias with potential for risk stratification of sudden death in Chagas 
disease 
 
8. Imaging modalities for risk stratification   
Echocardiography can provide key data to guide therapy and prognosis. Several 
echocardiographic variables have been described as predictors of mortality in Chagas 
disease98. Early studies have identified LV dysfunction and specially low ejection 
fraction obtained by echocardiography as the strongest predictor of death. 34, 45, 61, 62, 79 
Subsequently, echocardiographic parameters to assess LV filling pressure have been 
reported to have additive value for risk stratification of patients with impaired LV 
systolic function 79.  
The ratio of early transmitral velocity to tissue Doppler mitral annular early diastolic 
velocity (E/e’ ratio), an accepted noninvasive method to estimate LV filling pressures, 
is also an independent predictor of mortality in patients with CCM.44, 67, 75 
A previous study showed that the inclusion of the of E/e’ ratio has improved the risk 
prediction model beyond established risk parameters in patients with CCM including 
functional class, LV ejection fraction, and RV function 79. However, E/e’ ratio appears 
to have different effects on mortality in the setting of CCM 75. In patients with mild or 
moderate LV systolic dysfunction, an E/e’ ratio >15 was a powerful predictor of 
mortality. In contrast, in patients with severe systolic dysfunction, an increased E/e’ 
ratio was inversely associated with mortality 75. Although the underlying mechanism to 
explain these findings remains to be clarified, it suggests that Chagas disease has some 
specific features compared to heart failure from other etiologies.   
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Increased left atrial (LA) volume has been shown to be an independent predictor of 
survival in CCM, adding incremental prognostic value to clinical factors, LV ejection 
fraction, and Doppler-derived parameters of diastolic function.49 More recently, a study 
showed that LA contractile function assessed by peak negative global LA strain was an 
independent predictor of clinical events, defined as the occurrence of a combined 
endpoint of all-cause mortality, stroke, heart transplantation, atrial fibrillation, or 
admission for worsening HF or cardiac arrhythmias (Figure 18).67 Although LA 
conductive function was depressed in all groups of patients with the cardiac form, LA 
contractile function was depressed only in those with heart failure.67 
RV systolic dysfunction is an independent predictor of survival in patients with CCM, 
adding incremental prognostic value to clinical data and to the severity of LV 
dysfunction.77 
In summary, several echocardiographic variables have been associated with increased 
mortality (Table 3). 34, 67, 75, 98-107 The prognostic role of new echocardiographic 
techniques like speckle tracking echocardiography and three-dimensional 
echocardiography is promising but its ultimate usefulness for clinical purposes remains 
to be defined. 
Cardiac magnetic resonance may have a role to stratify patients at risk of ventricular 
arrhythmias and progression to heart failure by detecting and quantifying the extension 
of myocardial fibrosis.60, 65, 108, 109 
Radionuclide methods may improve risk stratification to define cardiac involvement in 
Chagas disease in patients with devices precluding cardiac magnetic resonance studies, 
and to identity perfusion defects and myocardial sympathetic denervation derangements 
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that are associated with progression of LV dysfunction and appearance of malignant 
ventricular arrhythmia.66, 93   
The main features suggestive of Chagas disease in patients living in non-endemic zones 
are shown in Table 4. These characteristics help physicians from outside Latin America 
to be aware of Chagas disease.  
Advantages and disadvantages of each imaging modality in the setting of Chagas 
disease are shown in Table 5. As echocardiography is widely available with relatively 
low cost, it became the imaging method of choice to evaluate patients with Chagas 
disease. An algorythm of diagnostic steps in Chagas disease and assessment periodicity 
is also shown in Panel A (on page 45). 
Key points 
- Presence and extension of LGE are predictive of severe ventricular 
arrhythmias, heart failure, and sudden death 
- It remains to be clarified whether in the patients with the indeterminate form 
of the disease, evidence of edema or fibrosis at CMR can predict future 
progression to the cardiomyopathy 
 
9. Conclusions and future research   
More than a hundred years after its discovery by the Brazilian scientist Carlos Chagas, 
Chagas disease continues to pose significant burden to affected people, mostly Latin 
American residents and immigrants to non-endemic areas including Europe, Japan, and 
the United States. The early mortality and substantial disability caused by this disease 
result in a significant economic impact. Cardiac imaging is crucial to detect the cardiac 
involvement in patients with Chagas disease, stage the disease and stratify patient risk 
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and address management. Since unfortunately, most patients live in regions with limited 
access to imaging methods and point-of-care, establishment of simplified protocols, 
could improve the access of these remote populations to important information provided 
by diagnostic methods that could impact in the clinical management of the disease.  
There are many fields open for further research in cardiac imaging in Chagas disease. 
The role of speckle tracking echocardiography to allow for an earlier diagnosis of 
cardiac involvement and improve patients’ risk stratification remains to be addressed in 
properly powered outcome studies. Although three-dimensional echocardiography 
should be theoretically more accurate than conventional two-dimensional 
echocardiography in measuring LV volumes and ejection fraction in ventricles with 
distorted geometries like those with regional aneurysms, whether this improved 
accuracy would translate into increased prognostic power remains to be proved. The 
role of three-dimensional echocardiography could be particularly useful to assess RV 
involvement and its prognostic impact. The prognostic role of the presence and 
extension of areas of myocardial edema and/or fibrosis by CMR to predict future 
progression to cardiomyopathy, heart failure, severe ventricular arrhythmias, and  
sudden death should be addressed in well-designed multicenter outcome studies.  
Finally, the role of myocardial perfusion scintigraphy and assessment of myocardial 
sympathetic innervation for an early diagnosis of cardiac involvement and prognosis in 
patients with Chagas disease remains to be established.  
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TABLES  
 
 
Table 1: Stages in the development of heart failure due to Chagas disease  
 Stages  Findings   
A Patients present no symptoms of heart failure, and no structural heart disease (normal 
ECG and chest x-ray) 
B1 Asymptomatic patients with ECG changes (arrhythmias or conduction disorders); 
mild echocardiographic contractile abnormalities with normal global ventricular 
function can also be present 
B2 Patients with impaired left ventricular ejection fraction who have never had any signs 
or symptoms of heart failure 
C Patients with left ventricular dysfunction and prior or current symptoms of heart 
failure  
D Patients with symptoms of heart failure at rest,  refractory to maximized medical 
therapy (NYHA IV) that require specialized and intensive interventions 
ECG = electrocardiogram; NYHA = New York Heart Association.  
Reference number: 42  
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Table 2: Score for predicting all-cause mortality  in Chagas disease (Rassi's score) 34 
Predictors   Points 
New York Heart Association class III or IV 5 
Cardiomegaly (chest x-ray) 5 
Segmental or global wall motion abnormality (echo)  3 
Nonsustained ventricular tachycardia (24h Holter) 3 
Low QRS voltage (ECG) 2 
Male sex 2 
Risk category  5-years mortality    10-years mortality    Total points 
Low 
 
2% 10% 0-6 
Intermediate 
 
18% 44% 7-11 
High 63% 84% 12-20 
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Table 3: Echocardiographic predictors of outcomes in Chagas disease  
Author/year No of 
patients 
Characteristics of Chagas 
disease patients  
Follow-up 
duration  
Outcomes Echocardiography 
predictive variables* 
Other prognostic 
factors  
Viotti (2005)99 856 Indeterminate form and heart 
disease, without heart failure  
8 y Progression of the disease 
or cardiovascular death 
LV end-systolic diameter Age, ICD, SVT and 
benznidazole treatment 
Rassi Jr. (2006)34  424 Heart disease   7.9 ± 3.2 y All cause-mortality LV systolic dysfunction 
subjectively estimated  
NYHA class, 
cardiomegaly, NSVT, 
QRS voltage and male  
Benchimol (2007)100 50 Indeterminate form and heart 
disease 
84.2 ± 39 m  Cardiac death or 
documented ventricular 
tachycardia 
Apical aneurysm and 
LVEF    
Isolated PVC count 
Theodoropoulos (2008)101 127 Heart failure with LV systolic 
dysfunction 
25 ± 19 m 
 
All cause-mortality LVEF  NYHA class IV, no  BB 
therapy, digoxine use, 
low serum sodium levels    
Issa (2010)102 † 68 Irreversible chronic heart 
failure    
1326 ± 39 d 
 
Death or heart   transplant LV end-diastolic 
diameter  
BB therapy 
Sarabanda (2011)103  56  Heart disease with either 
sustained VT or NSVT 
38 ± 16 m 
 
All cause-mortality and 
sudden death 
LVEF < 40% None  
Ribeiro (2011)104 113 Indeterminate form and heart 
disease 
106 ± 28 m Cardiovascular death LVEF   T-wave variability, 
NSVT and QSR > 130 
ms 
Bestetti (2011)105 231 Chronic heart failure  19 m Death or heart transplant LV end-systolic diameter   No BB therapy and 
inotropic support  
Duarte (2011)106 56 Dilated cardiomyopathy  21 ± 14 m 
 
Death or hospitalizaton  Rassi's score  LV dyssynchrony was 
not associated with 
events  
Nunes (2012)75 232 Dilated cardiomyopathy 3.4 y Death or heart   transplant LVEF, RVMPI, LA 
volume and E/e’ ratio 
NYHA class 
Nascimento (2013)67 251 Indeterminate form and heart 
disease 
842 ± 245 d All-cause mortality, stroke, 
heart transplant,  
worsening HF or 
arrhythmias 
E’ velocity and peak 
negative global LA strain 
None 
Carmo Rassi (2014)107 60  Heart failure with severe LV 
systolic dysfunction  
24 m Cardiovascular death Indexed LA volume None 
*multivariate analysis   
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†Clinical trial; 456 patients with heart failure were enrolled, and Chagas cardiomyopathy was present in 68 patients. AF = atrial fibrillation, BB = beta-blocker, CI =  
confidence interval, ICD = intraventricular conduction disorders, d = days, LA = left atrium, LVEDD = left ventricular end-diastolic diameter, LVSD = left ventricular end-
systolic diameter, LVEF = left ventricular ejection fraction, m = months, NYHA = New York Heart Association, QTd = QT dispersion, RVMPI = Right ventricular 
myocardial performance index, SVT = sustained ventricular tachycardia, NSVT = nonsustained ventricular tachycardia, VT = ventricular tachycardia, Y = years 
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Table 4: Characteristics suggestive of Chagas disease in patients living in non- endemic countries 
 
 
Epidemiological profile Individuals who were born in, or have lived in endemic areas or a child of a mother from 
endemic country. 
Clinical features Cardiac rhythm disorders, heart failure, thromboembolic events, chest pain without evidence of 
epicardial coronary artery disease. Association with megaoesophagus or megacolon. 
ECG abnormalities Sinus bradycardia, right bundle branch block with or without left anterior fascicular block, 
atrioventricular blocks, frequent premature ventricular beats, and primary ST and T wave 
abnormalities. 
Echocardiographic findings Segmental wall motion abnormalities, mainly inferior and inferolateral walls, left ventricular 
apical aneurysms, thrombus, and dilated cardiomyopathy with right ventricular dysfunction. 
Cardiac magnetic resonance (CMR) and 
nuclear imaging methods 
Myocardial fibrosis, regional myocardial perfusion defects and sympathetic denervation. 
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Table 5: Advantages and disadvantages of each imaging modality in Chagas disease  
Imaging modality Advantages Disadvantages 
Echocardiography - Widely available, relatively low cost, potentially portable 
- Allows evaluation of global and regional left ventricular 
systolic function, diastolic function, right ventricular 
involvement, atrioventricular valve regurgitation, recognition 
of intracardiac thrombus, and ventricular aneurysms 
- Sensitive to mild cardiac involvement, may detect cardiac 
involvement even in those with normal ECG 
- Many studies showing that can predict progression of the 
disease, risk of malignant arrhythmias and death 
- Speckle tracking longitudinal strain and 3D echocardiography 
is superior to conventional echo to assess more accurately and 
reproducibly left ventricular systolic function   
 
- Relatively low reproducibility of measurements 
- Highly dependent on the expertise of the examiner 
 
Cardiac magnetic 
resonance 
- Allows full evaluation of cardiac structure and function, 
including most aspects covered by the echo 
- Allows non-invasive tissue characterization, including 
myocardial edema and fibrosis 
- Very sensitive to early cardiac involvement 
- Predictive of severe ventricular arrhythmias, heart failure, and 
sudden death 
- Not widely available in endemic regions, high cost, non-portable 
- Highly specialized personnel required 
- Limited data on right ventricular function available 
- Limited data on the predictive value for progression of the disease 
and death 
Radionuclide 
ventriculography 
- Alternative method for global biventricular function 
assessment, as well as the recognition of ventricular aneurysms 
- Not widely available, high cost, non-portable 
- Highly specialized personnel required 
- No information about the cardiac muscle/walls 
Stress echocardiography - May detect stress-induced wall motion abnormalities and 
impaired coronary flow reserve early in the indeterminate 
form, in the absence of angiographic coronary artery disease 
- Uncertain clinical value of the findings 
- Dependent of examiner with high expertise  
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Myocardial Perfusion 
Scintigraphy 
- May detect cardiac perfusion abnormalities with normal 
coronary arteries, early in the indeterminate form, that can 
predict the presence of fibrosis and the deterioration of LV 
function 
- Not widely available in endemic regions, high cost, non-portable 
- Highly specialized personnel required 
- Limited data on the predictive value for progression of the disease 
and death 
Myocardial sympathetic 
innervation 
- May detect early sympathetic denervation in the indeterminate 
form 
- may be a marker of ventricular arrhythmias with potential for 
risk stratification of sudden death 
- Not widely available in endemic regions, high cost, non-portable 
- Highly specialized personnel required 
- Not routinely available in most centers 
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Panel A: Diagnostic flow chart and suggested periodicity of assessment 110 
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*Echocardiography should be repeated every 3 to 5 years in the patients with preserved left ventricular ejection fraction and more often in those 
who have reduced ejection fraction at the diagnosis or when clinical status change with worsening heart failure or embolic events. 24 hs  Holter 
monitor is specially recommendaded in patients with major ECG changes, including sinus node dysfunction, atrioventricular block, or frequent 
premature ventricular contractions, and should be repeated when clinical status change, or when with pre-syncope or syncope supervenes.  
Exercise testing at the diagnosis may be indicated: as a substitute for Holter when this method is not available, to detect arrythmia;  as a pre-
employment evaluation to guide physical activities; in those candidates for cardiac transplantation; it should be repeated  in those patients who 
develop new symptoms at the same periodicity as the Holter test. 
†  It can be done to assess myocardial perfusion or myocardial sympathetic innervation, mainly for patients who complain of atypical chest pain, 
so as to avoid unnecessary cardiac catheterization. It may also be useful to further stratify the risk of LV systolic deterioration and the appearance 
of malignant arrhythmia. No recommendation can be currently be set for its periodicity. 
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